Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
International Journal of Clinical Oncology|May 28, 2025
Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trialKoji Izutsu, Takahiro Kumode, Junichiro Yuda, et al.
Cancer Science|November 3, 2023
Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphomaKoji Izutsu, Takahiro Kumode, Junichiro Yuda, et al.
Annals of Hematology|February 3, 2026
Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trialYasmin H Karimi, Chan Y Cheah, Michael Roost Clausen, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 10, 2020
Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemiaAdam J Lamble, Yoko Kosaka, Ted Laderas, et al.
Leukemia|September 25, 2024
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trialCatherine Thieblemont, Yasmin H Karimi, Herve Ghesquieres, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 13, 2012
Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer riskFrancesca Demichelis, Sunita R Setlur, Samprit Banerjee, et al.
Haematologica|September 22, 2018
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUXMeletios A Dimopoulos, Jesus San-Miguel, Andrew Belch, et al.
Haematologica|September 22, 2018
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTORAndrew Spencer, Suzanne Lentzsch, Katja Weisel, et al.
Cancer Cell|July 16, 2015
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLCHelai P Mohammad, Kimberly N Smitheman, Chandrashekhar D Kamat, et al.
Cell|April 30, 2013
Punctuated evolution of prostate cancer genomesSylvan C Baca, Davide Prandi, Michael S Lawrence, et al.
Pageof 2